Functional Concept – Page 35

GSK Reports Mixed Results for Jemperli/Zejula Combination in First-Line Ovarian Cancer Trial

7 months ago talkbio0Tagged Clinical Trials, first-line, Jemperli, mixed survival data, ovarian neoplasm, SmithKline Beecham, Zejula

GSK, Jemperli, Zejula, ovarian cancer, first-line treatment, mixed survival data, clinical trial results

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

7 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

7 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists

7 months ago talkbio0Tagged Availability of, Compounders, Dosage Forms, Drug Shortage, Glucagon-Like Peptide 1, semaglutide, United States Food and Drug Administration

FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability

FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC

7 months ago talkbio0Tagged (ALK)-positive, Approved, ensartinib, Holdings, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, United States Food and Drug Administration, Xcovery

Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings

Astellas and Sangamo Therapeutics Partner to Enhance Neurological Gene Therapy with STAC-BBB Capsid

7 months ago talkbio0Tagged Astellas, Blood - brain barrier anatomy, genomic medicines, Neurological Gene Therapy, Penetration, STAC, STAC-BBB

Astellas, Sangamo Therapeutics, STAC-BBB capsid, neurological gene therapy, genomic medicines, blood-brain barrier penetration

Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends

7 months ago talkbio0Tagged Clinical Trials, exploration, Failure (biologic function), Parkinson 's disease, Prasinezumab, Roche (company), trends qualifier

Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

7 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

7 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations

7 months ago talkbio0Tagged AMD, Attitude, bevacizumab, biopharmaceutical company, cost-saving measures, Glycogen storage disease type II, Lytenava, restructuring, strategic

Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.